Your browser doesn't support javascript.
loading
[Effect of PPAR-γ agonist pioglitazone on the prolifeiration of malignant nesothelionma cells induced by HMGB1].
Wang, Y B; Shen, W; Gan, Y H; Zou, J; Zhang, Y; Zhu, L J; Ju, L; Jiang, Z Q; Ying, S B.
Afiliação
  • Wang YB; Hangzhou Medical College, Hangzhou 310013, China.
  • Shen W; Department of Respiratory Medicine, The Third People's Hospital of Cixi, Ningbo 315324, China.
  • Gan YH; Hangzhou Medical College, Hangzhou 310013, China.
  • Zou J; Hangzhou Medical College, Hangzhou 310013, China.
  • Zhang Y; Hangzhou Medical College, Hangzhou 310013, China.
  • Zhu LJ; Hangzhou Medical College, Hangzhou 310013, China.
  • Ju L; Hangzhou Medical College, Hangzhou 310013, China.
  • Jiang ZQ; Hangzhou Medical College, Hangzhou 310013, China.
  • Ying SB; Hangzhou Medical College, Hangzhou 310013, China.
Article em Zh | MEDLINE | ID: mdl-34624942
ABSTRACT

Objective:

To investigate the effect and mechanism of PPAR-γ agonist Pioglitazone (PGZ) on the proliferation of malignant mesothelioma (MM) cells.

Methods:

In December 2019, MM cell lines MSTO-211H and NCI-H2452 were incubated with different final concentrations of PGZ (0, 10, 50, 100, 150, and 200 µmol/L) for different periods of time (24 h, 48 h, and 72 h) , and then the cell proliferation level was detected by CCK8 assay. After given various final concentration of PGZ (0, 10, 50, 100, 150, 200 µmol/L) the for 72 hours, the changes of number and morphology of MM cells were observed under an inverted microscope. The expressions of PPAR-γ and HMGB1 mRNA were determined by real-time fluorescence quantitative reverse transcription-polymerase chain reaction (qRT-PCR) after treatment of MM cells with PGZ of 0, 10, 50, 100 µmol/L for 72 h. The MM cells were treated with PGZ at concentration of 0, 100 µmol/L for 72 h, and the protein expressions of HMGB1 were examined using Western blotting and immunofluorescence; the protein expressions of Ki67 were assessed by immunohistochemistry.

Results:

The cell viability rate of MM cells was decreased after treated with PGZ (P<0.05) . Cell number in PGZ-treated group was significantly less than that in control group and morphology changes were observed under light microscope. QRT-PCR results revealed significantly increased PPAR-γ mRNA expression in the PGZ-treated group compared to the control group (P<0.05) . There was a significant decrease in the mRNA expression level of HMGB1 in the PGZ-treated group (100 µmol/L) as compared to the control group in MSTO-211H (P<0.05) ; however, the expression level of HMGB1 in NCI-H2452 was an increase or no significant differences (P>0.05) . Western blotting and immunofluorescence results showed that the protein expression of HMGB1 was reduced in the PGZ-treated group compared with the control group in MSTO-211H (P<0.05) , but the protein expression of that in NCI-H2452 was no significant differences (P>0.05) . Immunohistochemistry results showed increased expression of proliferation marker Ki-67.

Conclusion:

Pioglitazone suppresses the proliferation of MM cells through inhibition of HMGB1 by the activation of PPAR-γ.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína HMGB1 / PPAR gama / Pioglitazona / Mesotelioma Limite: Humans Idioma: Zh Revista: Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi Assunto da revista: MEDICINA OCUPACIONAL Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína HMGB1 / PPAR gama / Pioglitazona / Mesotelioma Limite: Humans Idioma: Zh Revista: Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi Assunto da revista: MEDICINA OCUPACIONAL Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China